Jun 4, 2024, 16:31
Just presented at ASCO24: IMROZ results by C. Ola Landgren – ASCO
ASCO shared a post on X:
“Just presented at American Society of Clinical Oncology 2024 (ASCO24), IMROZ results- lsatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) significantly improved Progression-Free Survival (PFS) in patients with transplant-ineligible, newly diagnosed Multiple Myeloma versus Velcade, Revlimid and dexamethasone (VRd) with no new safety concerns.”
Additional information
Source: ASCO/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 09:06
Dec 21, 2024, 09:00
Dec 21, 2024, 08:51
Dec 21, 2024, 08:48
Dec 21, 2024, 08:42
Dec 21, 2024, 08:37
Dec 21, 2024, 08:29
Dec 21, 2024, 08:12
Dec 21, 2024, 07:45